Does Finasteride Cause Mood Swings or Depression?
There appears to be significant confusion in your question: Finasteride is NOT a combined oral contraceptive—it is a 5-alpha reductase inhibitor used for male pattern baldness and benign prostatic hyperplasia in men. The drug you may be asking about is likely a combined oral contraceptive (COC) containing ethinyl estradiol and norgestrel, not finasteride.
If You're Asking About Finasteride (for men):
Finasteride's FDA label does not list depression or mood swings as adverse reactions, though post-marketing reports exist. The FDA label for finasteride reports that the most frequently reported adverse reactions are related to sexual function (impotence, decreased libido, ejaculation disorders), not mood disturbances 1. Mental depression is not listed among the documented adverse reactions in controlled trials.
If You're Asking About Combined Oral Contraceptives (COCs):
Yes, combined oral contraceptives are associated with increased risk of depression and mood disturbances, particularly in adolescents and women with prior negative hormonal contraceptive experiences.
Key Evidence on COCs and Mood:
The strongest and most recent evidence comes from a 2016 nationwide Danish cohort study of over 1 million women, which found that COC users had a 23% increased risk of first antidepressant use compared to non-users (RR 1.23,95% CI: 1.22-1.25). 2 This risk was substantially higher in adolescents aged 15-19 years (RR 1.8,95% CI: 1.75-1.84), with the peak risk occurring 6 months after starting hormonal contraception.
Specific Mood Effects by Phase:
Intermenstrual phase: A 2017 randomized, double-blind, placebo-controlled trial demonstrated that COC use causes small but statistically significant increases in anxiety (0.22 increase, p=0.003), irritability (0.23 increase, p=0.012), and mood swings (0.15 increase, p=0.047) during the intermenstrual phase 3
Premenstrual phase: The same study found COCs actually improved premenstrual depression (-0.33, p=0.049), suggesting differential effects across the cycle 3
High-Risk Populations:
Women with previous adverse hormonal contraceptive experiences are at significantly greater risk for mood worsening when restarting COCs 3. A 2013 double-blind trial specifically in women with prior COC-induced mood problems found that re-exposure resulted in higher scores of depressed mood, mood swings, and fatigue compared to placebo, along with measurable changes in emotional brain reactivity on fMRI 4.
Clinical Implications:
- Counsel all women starting COCs about potential mood effects, emphasizing higher risk in adolescents and those with prior hormonal sensitivity
- Monitor closely during the first 6 months, when risk peaks
- Consider alternative contraception (such as copper IUD) for women with history of depression or prior COC-related mood symptoms
- Document baseline mood and follow up systematically
Common Pitfall:
The FDA label for ethinyl estradiol lists "mental depression" under adverse reactions but notes the association "has been neither confirmed nor refuted" 5. However, this outdated language contradicts the robust epidemiological evidence from large-scale studies showing clear associations 2.
Bottom line: If prescribing COCs, inform patients about the 23% increased depression risk, which is higher in adolescents (80% increase) and peaks at 6 months of use.